Share this
consumer blood testing: life after theranos
by Neoteryx Microsampling on Jun 3, 2019 6:02:00 AM
Over the past few decades, a need for better and more efficient healthcare delivery has been on the rise. As a result, there has been an influx of devices and applications developed all in the hopes of delivering smarter healthcare.
However, with the need to accomplish big things with high expectations and tight turnarounds, the healthcare sector has fallen victim to companies that have promised to deliver that but have failed, offering empty promises. A good example is Theranos. Despite these, there are others who have managed to deliver amidst all the challenges.
1. Diagnostic Test Strips
New test strip devices are reportedly able to diagnose various diseases including flu, bacterial infections, and cancer. For cancer diagnosis, the device is being used to monitor the white blood cells count for patients undergoing chemotherapy. A typical such device uses a single drop of blood to capture high-resolution images and the collective white blood cell count using artificial intelligence. With the information obtained from the test regarding white blood cells, it is possible to prescribe patients with cell-boosting medication.
2. New Pregnancy Tests
Pregnancy tests have come a long way. Unlike traditional pregnancy testing devices, a new one may use a drop of blood and produce results in 10 minutes. With this device, the results are definitive as they are determined by the presence of hCG. One does not need to go to the lab to confirm the results.
3. Asthma Innovations
Innovative mobile phone applications may be useful to patients living with asthma. Asthma attacks happen at different times and are of varied magnitude. New applications help patients manage the disease. When these systems work as intended, a patient is able to record symptoms of an attack, what triggered it, and the rates of wheezing. This helps set times to take medication or do testing, and gives a patient an increased sense of agency and power over the condition.
4. More Convenient Blood Microsampling
The Mitra® device, driven by Volumetric Absorptive Microsampling (VAMS™) technology, is a prime example of a new medical technology that can do a lot with a little. By collecting precise volumes of dried blood (or another biological fluid), it eliminates the hematocrit bias, cold-chain shipping, and other traditional impediments to the use of small samples. In so doing, it provides a missing link between the most exciting ideas in healthtech and telemedicine and the stuff of human life, the fluids that keep us vital. It allows our lifeforce to drive healthcare innovation, and enables the scientists and companies leading the next wave of clinical testing.
With these applications and more, it is possible for consumers to quickly get some of the important services that they would alternatively spend hours going to health facilities or laboratories to get. Application of these is, therefore, improving the lives of consumers in more ways than before and we can always hope to see more of these. The transgressions of Theranos shouldn't impede this progress.
Learn more about microsampling for clinical studies, preclinical studies, patient monitoring and more here:
Share this
- Microsampling (206)
- Research, Remote Research (118)
- Venipuncture Alternative (106)
- Clinical Trials, Clinical Research (83)
- Mitra® Device (73)
- Therapeutic Drug Monitoring, TDM (50)
- Dried Blood Spot, DBS (38)
- Biomonitoring, Health, Wellness (31)
- Infectious Disease, Vaccines, COVID-19 (24)
- Decentralized Clinical Trial (DCT) (22)
- Blood Microsampling, Serology (21)
- Omics, Multi-Omics (19)
- Specimen Collection (17)
- Toxicology, Doping, Drug/Alcohol Monitoring, PEth (17)
- hemaPEN® Device (13)
- Preclinical Research, Animal Studies (12)
- Pharmaceuticals, Drug Development (9)
- Harpera® Tool (7)
- Skin Microsampling, Microbiopsy (6)
- Industry News, Microsampling News (5)
- Antibodies, MAbs (3)
- Company Press Release, Product Press Release (3)
- Environmental Toxins, Exposures (1)
- June 2024 (1)
- May 2024 (1)
- April 2024 (4)
- March 2024 (1)
- February 2024 (2)
- January 2024 (4)
- December 2023 (3)
- November 2023 (3)
- October 2023 (3)
- September 2023 (3)
- July 2023 (3)
- June 2023 (2)
- April 2023 (2)
- March 2023 (2)
- February 2023 (2)
- January 2023 (3)
- December 2022 (2)
- November 2022 (3)
- October 2022 (4)
- September 2022 (3)
- August 2022 (5)
- July 2022 (2)
- June 2022 (2)
- May 2022 (4)
- April 2022 (3)
- March 2022 (3)
- February 2022 (4)
- January 2022 (5)
- December 2021 (3)
- November 2021 (5)
- October 2021 (3)
- September 2021 (3)
- August 2021 (4)
- July 2021 (4)
- June 2021 (4)
- May 2021 (4)
- April 2021 (3)
- March 2021 (5)
- February 2021 (4)
- January 2021 (4)
- December 2020 (3)
- November 2020 (5)
- October 2020 (4)
- September 2020 (3)
- August 2020 (3)
- July 2020 (6)
- June 2020 (4)
- May 2020 (4)
- April 2020 (3)
- March 2020 (6)
- February 2020 (3)
- January 2020 (4)
- December 2019 (5)
- November 2019 (4)
- October 2019 (2)
- September 2019 (4)
- August 2019 (4)
- July 2019 (3)
- June 2019 (7)
- May 2019 (6)
- April 2019 (5)
- March 2019 (6)
- February 2019 (5)
- January 2019 (8)
- December 2018 (3)
- November 2018 (4)
- October 2018 (7)
- September 2018 (6)
- August 2018 (5)
- July 2018 (8)
- June 2018 (6)
- May 2018 (5)
- April 2018 (6)
- March 2018 (4)
- February 2018 (6)
- January 2018 (4)
- December 2017 (2)
- November 2017 (3)
- October 2017 (2)
- September 2017 (4)
- August 2017 (2)
- July 2017 (4)
- June 2017 (5)
- May 2017 (6)
- April 2017 (6)
- March 2017 (5)
- February 2017 (4)
- January 2017 (1)
- July 2016 (3)
- May 2016 (1)
- April 2016 (2)
Comments (1)